05 May 2015
The average upfront value in biotech deals hit a 9-year peak in 2014, according to Morrison & Foerster, part of a virtuous cycle in life sciences that has pushed asset valuations ever upward.
In its latest BioMeter Index, Morrison & Foerster notes that the average down payment swelled to $58.7 million per deal last year, a 73% jump over 2013's $33.9 million and the highest figure clocked since the firm started keeping track in 2006. Merck's ($MRK) head-turning $1 billion upfront for a handful of Bayer cardio assets inflated 2014's results a bit, but, even removing that outlier, the year's average tops anything Morrison & Foerster has ever tracked, the firm said.
The spike provides yet more evidence of the industry's current high tide. As ever, Big Pharma has wide gaps in its pipeline and needs biotech's help, but the enthusiastic reception for drug developers on Wall Street has provided both a near-term liquidity option for investors and a lever for boosting the valuations of startups and their assets. The result, as BioMeter illustrates, is a seller's market.
Last year's value surge was spread out across all areas of development. Preclinical transactions hit a 9-year high at $28 million on average, while Phase I deals leapt 13% to $45 million, and Phase II upfronts increased 77% to $83.5 million. Phase III asset values jumped from $46 million in 2013 to $101 million, and approved products more than quadrupled to $213 million, but only 6 such deals took place, Morrison & Foerster notes.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
New breast cancer guidelines call for first mammogram at age 40 but stop short of annual screening
08 May 2024
WHO proposes recommendations for preventing nitrosamine contamination
07 May 2024
Batyr Berdyklychev is now head of the WHO office in Russia
07 May 2024
Russia expects more medical tourism due to the world’s first drug for ankylosing spondylitis
07 May 2024